LGND Q1 2019 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M-22.6% YoY

Gross Profit

$40M91.1% margin

Operating Income

$827M1900.8% margin

Net Income

$666M1532.4% margin

EPS (Diluted)

$31.32

QoQ Revenue Growth

-27.0%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$45M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$834M

Stockholders' Equity

$1.1B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$56M	-22.6%
Gross Profit	$40M	$55M	-28.4%
Operating Income	$827M	$37M	+2131.4%
Net Income	$666M	$45M	+1371.6%

Revenue Segments

Promacta

$14M100%